Biofilm production using distinct media and antimicrobial susceptibility profile of Pseudomonas aeruginosa
- PMID: 21860998
- DOI: 10.1016/s1413-8670(11)70196-9
Biofilm production using distinct media and antimicrobial susceptibility profile of Pseudomonas aeruginosa
Abstract
Biofilm production is an important mechanism for bacterial survival and its occurrence together with antimicrobial resistance represents a challenge for clinical management. Here, we evaluated the ability for biofilm production among P. aeruginosa isolates from patients with or without cystic fibrosis (CF) using two distinct media, besides determining the antimicrobial susceptibility profile of these isolates for eight antimicrobial agents. The ability for biofilm production when TSB medium was used was higher than when used CF sputum media (p = 0.0198). However, P. aeruginosa isolates from CF have demonstrated similar performance for biofilm production, independently of the medium used. Besides, among the biofilm-producing isolates, those recovered from CF were more resistant to the carbapenems (meropenem and imipenem) agents than those isolates from non-CF isolates.
Similar articles
-
Integron types, antimicrobial resistance genes, virulence gene profile, alginate production and biofilm formation in Iranian cystic fibrosis Pseudomonas aeruginosa isolates.Infez Med. 2018 Sep 1;26(3):226-236. Infez Med. 2018. PMID: 30246765
-
Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.J Clin Microbiol. 2005 Oct;43(10):5085-90. doi: 10.1128/JCM.43.10.5085-5090.2005. J Clin Microbiol. 2005. PMID: 16207967 Free PMC article.
-
Use of artificial sputum medium to test antibiotic efficacy against Pseudomonas aeruginosa in conditions more relevant to the cystic fibrosis lung.J Vis Exp. 2012 Jun 5;(64):e3857. doi: 10.3791/3857. J Vis Exp. 2012. PMID: 22711026 Free PMC article.
-
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.Cochrane Database Syst Rev. 2012 Nov 14;11:CD009528. doi: 10.1002/14651858.CD009528.pub2. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2015 Mar 05;(3):CD009528. doi: 10.1002/14651858.CD009528.pub3 PMID: 23152277 Updated. Review.
-
Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway.Pulm Pharmacol Ther. 2008 Aug;21(4):595-9. doi: 10.1016/j.pupt.2007.12.001. Epub 2008 Jan 29. Pulm Pharmacol Ther. 2008. PMID: 18234534 Free PMC article. Review.
Cited by
-
Effects of Lysozyme, Proteinase K, and Cephalosporins on Biofilm Formation by Clinical Isolates of Pseudomonas aeruginosa.Interdiscip Perspect Infect Dis. 2020 Feb 8;2020:6156720. doi: 10.1155/2020/6156720. eCollection 2020. Interdiscip Perspect Infect Dis. 2020. PMID: 32089678 Free PMC article.
-
Use of a fundamental approach to spray-drying formulation design to facilitate the development of multi-component dry powder aerosols for respiratory drug delivery.Pharm Res. 2014 Feb;31(2):449-65. doi: 10.1007/s11095-013-1174-5. Epub 2013 Aug 23. Pharm Res. 2014. PMID: 23974958
-
Pathogenicity of ocular isolates of Acinetobacter baumannii in a mouse model of bacterial endophthalmitis.Invest Ophthalmol Vis Sci. 2014 Apr 15;55(4):2392-402. doi: 10.1167/iovs.13-13401. Invest Ophthalmol Vis Sci. 2014. PMID: 24644055 Free PMC article.
-
The Impact of Cultivation Media on the In Vitro Biofilm Biomass Production of Candida spp.Curr Microbiol. 2021 May;78(5):2104-2111. doi: 10.1007/s00284-021-02452-6. Epub 2021 Mar 25. Curr Microbiol. 2021. PMID: 33765192
-
A Shaving Proteomic Approach to Unveil Surface Proteins Modulation of Multi-Drug Resistant Pseudomonas aeruginosa Strains Isolated From Cystic Fibrosis Patients.Front Med (Lausanne). 2022 Mar 9;9:818669. doi: 10.3389/fmed.2022.818669. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35355602 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
